Clinical Trials associated with Suzhou Hengrui Jialisheng Biopharmaceutical Technology Co
ChiCTR1900025295
/ Not yet recruitingEarly Phase 1IIT
Prospective, multi-center, single-arm clinical study of CalliSpheres drug-loaded embolization microspheres in the treatment of locally advanced non-small cell lung cancer after chemotherapy failure
Efficacy, safety and prognosis analysis of transarterial chemoembolization with CalliSpheres drug-eluting bead loaded with raltitrexed for hepatocellular carcinoma
100 Clinical Results associated with Suzhou Hengrui Jialisheng Biopharmaceutical Technology Co
Login to view more data
0 Patents (Medical) associated with Suzhou Hengrui Jialisheng Biopharmaceutical Technology Co
Login to view more data
1
Literatures (Medical) associated with Suzhou Hengrui Jialisheng Biopharmaceutical Technology Co
20 Jul 2016·Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
[Development of CalliSpheres® embolic microspheres].
Article
Author: Jin, Y ; Guan, Y S ; He, Q ; Yao, F
CalliSpheres® embolic microspheres for embolization of the vasculature of liver cancer are designed, manufactured, and verified, in order to improve the effect of transcatheter arterial chemoembolization in the treatment of primary liver cancer.
100 Deals associated with Suzhou Hengrui Jialisheng Biopharmaceutical Technology Co
Login to view more data
100 Translational Medicine associated with Suzhou Hengrui Jialisheng Biopharmaceutical Technology Co
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.